



Financial Statements

Lymphoma Canada

December 31, 2025

Contents

	Page
Independent Auditor's Report	1 - 2
Statement of Financial Position	3
Statement of Revenue and Expenses	4
Statement of Changes in Net Assets	5
Statement of Cash Flows	6
Notes to the Financial Statements	7 - 11
Schedule 1 - Schedule of Detailed Expenses	12

Independent Auditor's Report

To the Directors of
Lymphoma Canada

Qualified opinion

We have audited the financial statements of Lymphoma Canada (the "Organization"), which comprise the statement of financial position as at December 31, 2025, and the statements of revenue and expenses, changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the *Basis for qualified opinion* section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as at December 31, 2025, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for qualified opinion

We were not able to complete audit procedures to satisfy ourselves concerning the completeness of donation revenues for the year ended December 31, 2024. Verification of these revenues was limited to amounts recorded in the records of the Organization. Therefore, we were not able to determine whether any adjustments might be necessary to donation revenue or excess of revenues over expenses, and cash flows from operations for the year ended December 31, 2024, current assets as at December 31, 2024 and net assets as at January 1, 2024 and December 31, 2024. Our audit opinion on the financial statements for the year ended December 31, 2024 was modified accordingly. Our opinion on the current year's financial statements is also modified because of the possible effects of this matter on the comparability of the current period's figures and the corresponding figures.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Organization or to cease operations, or has no realistic alternative but to do so.

Independent Auditor's Report (continued)

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Mississauga, Canada
June 24, 2026

Doane Grant Thornton LLP

Chartered Professional Accountants
Licensed Public Accountants

Lymphoma Canada

Statement of Financial Position

December 31

2025

2024

Assets

Current

Cash	\$ 1,648,099	\$ 1,723,567
Short-term investments (Note 3)	142,000	313,313
Amounts receivable	28,060	80,808
Sales tax recoverable	14,938	15,094
Inventory	10,869	7,117
Prepaid expenses	<u>28,948</u>	<u>11,996</u>
	<u>1,872,914</u>	<u>2,151,895</u>
Long-term investments (Note 3)	550,000	82,000
Capital assets and intangible assets (Note 4)	<u>9,557</u>	<u>17,377</u>
	<u>559,557</u>	<u>99,377</u>
	<u>\$ 2,432,471</u>	<u>\$ 2,251,272</u>

Liabilities

Current

Accounts payable and accrued liabilities	\$ 70,369	\$ 78,484
Deferred contributions (Note 5)	89,349	74,112
Deferred lease inducement	<u>1,211</u>	<u>3,678</u>
	<u>160,929</u>	<u>156,274</u>
Net assets		
Unrestricted	1,840,142	1,663,598
Internally restricted operating reserve	<u>431,400</u>	<u>431,400</u>
	<u>2,271,542</u>	<u>2,094,998</u>
	<u>\$ 2,432,471</u>	<u>\$ 2,251,272</u>

Lease commitment (Note 9)

On behalf of the Board of Directors



Director



Director

Lymphoma Canada

Statement of Revenue and Expenses

Year ended December 31

	2025	2024
Revenue		
Educational grants from corporations	\$ 607,000	\$ 613,607
Contributions and fundraising	510,405	460,192
Bequest	50,000	225,000
Interest and miscellaneous	47,217	53,539
Government grant	<u>5,383</u>	<u>5,186</u>
	<u>1,220,005</u>	<u>1,357,524</u>
Expenses (Schedule 1)		
Program		
HCP & patient education	282,742	225,295
Patient support	182,943	171,565
Research	61,946	65,567
Advocacy	<u>48,988</u>	<u>38,368</u>
	<u>576,619</u>	<u>500,795</u>
Fundraising	316,158	253,707
Operations	<u>150,684</u>	<u>154,155</u>
	<u>466,842</u>	<u>407,862</u>
	<u>1,043,461</u>	<u>908,657</u>
Excess of revenue over expenses	<u>\$ 176,544</u>	<u>\$ 448,867</u>

Lymphoma Canada

Statement of Changes in Net Assets

Year ended December 31

	Unrestricted	Internally restricted operating reserve	Total 2025	Total 2024
Balance, beginning of year	\$ 1,663,598	\$ 431,400	\$ 2,094,998	\$ 1,646,131
Excess of revenue over expenses	<u>176,544</u>	<u>-</u>	<u>176,544</u>	<u>448,867</u>
Balance, end of year	<u>\$ 1,840,142</u>	<u>\$ 431,400</u>	<u>\$ 2,271,542</u>	<u>\$ 2,094,998</u>

Lymphoma Canada

Statement of Cash Flows

Year ended December 31

2025

2024

Increase (decrease) in cash

Operating

Excess of revenue over expenses	\$ 176,544	\$ 448,867
Item not affecting cash		
Amortization of capital assets and intangible assets	<u>7,820</u>	<u>5,130</u>
	184,364	453,997
Change in non-cash working capital items		
Amounts receivable	52,748	(24,016)
Sales tax recoverable	156	(2,224)
Inventory	(3,752)	500
Prepaid expenses	(16,952)	8,958
Accounts payable and accrued liabilities	(8,114)	11,897
Deferred contributions	15,237	(10,312)
Deferred lease inducement	<u>(2,467)</u>	<u>(1,849)</u>
	<u>221,220</u>	<u>436,951</u>

Investing

Purchase of capital assets and intangible assets	-	(22,422)
Purchase of investments (net)	<u>(296,688)</u>	<u>(97,534)</u>
	<u>(296,688)</u>	<u>(119,956)</u>

(Decrease) increase in cash

(75,468) 316,995

Cash

Beginning of year	<u>1,723,567</u>	<u>1,406,572</u>
End of year	<u>\$ 1,648,099</u>	<u>\$ 1,723,567</u>

Lymphoma Canada

Notes to the Financial Statements

December 31, 2025

1. Nature of operations

Lymphoma Canada (the "Organization") was incorporated without share capital on February 6, 1998, by Letters Patent under the Canadian Corporations Act and continued under the Canada Not-for-profit Corporations Act on October 17, 2013. The Organization is a registered charity under the Income Tax Act. The Organization's mission is to empower patients and the lymphoma community through education, support, advocacy, and research.

2. Significant accounting policies

The financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations. The significant accounting policies used are as follows:

Revenue recognition

The Organization follows the deferral method of accounting for contributions and grants. Unrestricted contributions and grants are recognized when received or receivable and collectability is reasonably assured. Revenue from fundraising is recognized when received or receivable and collectability is reasonably assured. Interest income is recognized as earned. Designated contributions and grants are recognized as revenue in the year in which the related expenses are incurred. All other revenue is recognized as earned.

Inventory

Inventory is measured at the lower of cost and net realizable value.

Capital assets and intangible assets

Capital assets are recorded at cost and are being amortized over the estimated useful life. The annual amortization rates and methods are as follows:

Furniture and fixtures	5 years Straight-line
Leasehold improvements	5 years Straight-line
Computer equipment	45% Declining balance

Intangible assets are recorded at cost and are being amortized over the estimated useful life. The annual amortization rate and method is as follows:

Website software and applications	3 years Straight-line
-----------------------------------	-----------------------

Impairment of long-lived assets

Capital and intangible assets are tested for impairment when events or changes in circumstances indicate that an asset might be impaired. The assets are tested for impairment by comparing the net carrying value to its fair value or replacement cost. If the asset's fair value or replacement cost is determined to be less than its net carrying value, the resulting impairment is reported in the statement of revenue and expenses. Any impairment recognized is not reversed.

Lymphoma Canada

Notes to the Financial Statements

December 31, 2025

2. Significant accounting policies (continued)

Lease benefit

During 2021, the Organization entered into a new lease agreement. The lease benefit includes a rent free period near the beginning of the lease. The lease benefit has been deferred and will be amortized and recognized as a reduction of rent expense over the term of the lease. The Organization recognizes the related rental expense on a straight-line basis over the life of the lease and records the difference between amounts charged to operations and amounts paid as deferred lease benefit.

Internally restricted operating reserve

The Board designated an internally restricted operating reserve to set aside six months of operating expenses.

Donated gifts and services

Donated services are not recognized in these financial statements due to the difficulty in determining their fair value. Donated gifts were received during the year but are not recognized in the financial statements.

Included in contributions on the statement of revenue and expenses and changes in net assets is \$59,969 (2024 - \$18,098) in donated shares.

Financial instruments

The Organization considers any contract creating a financial asset, liability or equity instrument as a financial instrument, except in limited circumstances. The Organization's financial instruments consists of cash, short-term investments, amounts receivable, sales tax recoverable and accounts payable.

Financial assets and financial liabilities in related party transactions are initially measured at cost, with the exception of certain instruments which are initially measured at fair value.

The Organization subsequently measures all of its financial assets and financial liabilities at cost or amortized cost. For financial assets measured at cost or amortized cost, the Organization regularly assesses whether there are any indications of impairment. Any impairment loss is recognized in the statement of revenue and expenses.

The Organization removes financial liabilities, or a portion thereof, when the obligation is discharged, cancelled or expires.

Allocation of expenses

Certain employees perform a combination of program, fundraising and administrative roles and as a result, salaries are allocated according to time spent on the activity. Other costs including rent, IT support, amortization and telephone are allocated based on the level of activity between program, fundraising and administrative costs.

Lymphoma Canada

Notes to the Financial Statements

December 31, 2025

2. Significant accounting policies (continued)

Use of estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Significant items subject to estimates and assumptions include the allowance for doubtful accounts receivable, amortization of capital assets and intangible assets and the allocation of expenses. Actual results could differ from those estimates.

3. Investments

Short-term investments consist of Guaranteed Investment Certificates (GICs) bearing interest at 3.00% to 3.75%, maturing May 2026 to December 2026 (2024 - bearing interest at 3.70% to 5.25%, maturing March 2025 to December 2025).

Long-term investments consist of GICs bearing interest at 2.90% to 3.00%, maturing April 2027 to December 2028 (2024 - bearing interest at 3.75%, maturing December 2026).

4. Capital assets and intangible assets

			<u>2025</u>	<u>2024</u>
	<u>Cost</u>	<u>Accumulated Amortization</u>	<u>Net Book Value</u>	<u>Net Book Value</u>
Furniture and fixtures	\$ 18,093	\$ 18,093	\$ -	\$ -
Leasehold improvements	9,887	9,887	-	-
Computer equipment	<u>37,610</u>	<u>28,053</u>	<u>9,557</u>	<u>17,377</u>
	65,590	56,033	9,557	17,377
Website software and applications	<u>145,210</u>	<u>145,210</u>	<u>-</u>	<u>-</u>
	<u>\$ 210,800</u>	<u>\$ 201,243</u>	<u>\$ 9,557</u>	<u>\$ 17,377</u>

Lymphoma Canada

Notes to the Financial Statements

December 31, 2025

5. Deferred contributions

Deferred contributions includes designated contributions to be recognized as revenue in the accounts when disbursed.

	<u>2025</u>	<u>2024</u>
Deferred contributions, beginning of year	\$ 74,112	\$ 84,424
Amounts received during the year	115,875	104,918
Amounts recognized as revenue during the year	<u>(100,638)</u>	<u>(115,230)</u>
	<u>\$ 89,349</u>	<u>\$ 74,112</u>

6. Allocation of expenses

The following are direct and allocated expenses which are included in the statement of revenue and expenses:

	<u>Direct expenses</u>	<u>Allocated expenses</u>	<u>2025</u>	<u>2024</u>
HCP & patient education	\$ 72,451	\$ 210,291	\$ 282,742	\$ 225,295
Patient support	3,703	179,240	182,943	171,565
Research	46,093	15,852	61,946	65,567
Advocacy	2,091	46,897	48,988	38,368
Fundraising	126,965	189,194	316,158	253,707
Operations	<u>58,588</u>	<u>92,096</u>	<u>150,684</u>	<u>154,155</u>
	<u>\$ 309,891</u>	<u>\$ 733,570</u>	<u>\$ 1,043,461</u>	<u>\$ 908,657</u>

7. Research awards

The following research awards were paid during the year:

	<u>2025</u>	<u>2024</u>
University Health Network	<u>\$ 45,638</u>	<u>\$ 50,000</u>

8. Financial instruments

Transactions in financial instruments may result in an entity assuming or transferring to another party one or more of the financial risks described below. The required disclosures provide information that assists users of financial statements in assessing the extent of risk related to financial instruments. The risks that arise from financial instruments include credit, liquidity, and interest rate risk. There have been no changes in the financial risks from the prior year.

Lymphoma Canada

Notes to the Financial Statements

December 31, 2025

8. Financial instruments (continued)

Credit risk

Credit risk is the risk that one party to a transaction will fail to discharge an obligation and cause the other party to incur a financial loss. This risk is mitigated by the Organization ensuring revenue is derived from qualified sources. There is no allowance for doubtful accounts in relation to the Organization's amounts receivable balances reflected in these financial statements.

Liquidity risk

Liquidity risk is the risk that the Organization cannot repay its obligations when they become due to its creditors. The Organization reduces its exposure to liquidity risk by ensuring that it documents when authorized payments become due. Included in accounts payable and accrued liabilities are government remittances owing in the amount of \$Nil (2024 – \$Nil).

Interest rate risk

Interest rate risk is the risk that the fair value or future value of a financial instrument will fluctuate because of changes in market interest rates. The Organization is subject to interest rate risk on their fixed income investments.

9. Lease commitment

Effective May 1, 2026, the Organization has committed to a revised rental agreement for its office premises with a term that expires on May 31, 2031. Lease commitments for the next five years and thereafter are as follows:

2026	\$	61,373
2027		67,155
2028		62,553
2029		62,862
2030		63,082
Subsequent years		<u>26,284</u>
	\$	<u>343,309</u>

Lymphoma Canada

Schedule of Detailed Expenses

Schedule 1

Year ended December 31	2025	2024
HCP & patient education		
Education patient	\$ 271,233	\$ 214,417
Education – HCP	9,436	9,403
Amortization	<u>2,073</u>	<u>1,475</u>
	\$ 282,742	\$ 225,295
Patient support		
Program support	\$ 180,863	\$ 170,487
Amortization	1,555	1,078
Chapter development	<u>525</u>	<u>-</u>
	\$ 182,943	\$ 171,565
Research		
Grant awards (Note 7)	\$ 45,638	\$ 50,000
Program support	16,143	15,457
Amortization	<u>165</u>	<u>110</u>
	\$ 61,946	\$ 65,567
Advocacy		
Program support	\$ 48,600	\$ 38,149
Amortization	<u>388</u>	<u>219</u>
	\$ 48,988	\$ 38,368
Fundraising		
Salaries and benefits	\$ 152,652	\$ 121,906
Sales and events	146,139	118,891
Bank charges	5,007	3,567
Website development	4,657	3,733
Board – strategic planning	3,675	4,091
Amortization	2,316	1,228
Corporate donations	<u>1,712</u>	<u>291</u>
	\$ 316,158	\$ 253,707
Operations		
Salaries and benefits	\$ 78,542	\$ 68,424
Rent, insurance and office supplies	34,832	43,539
Professional and consulting fees	21,316	22,149
Web site support and development - operations	7,262	9,239
Storage	4,685	5,088
Board	2,100	4,696
Amortization	1,324	1,020
Advertising	<u>623</u>	<u>-</u>
	\$ 150,684	\$ 154,155